Gallant Partners with MWI Animal Health to Establish First Ultra-Low Temperature Cold Chain for Veterinary Stem Cell Therapy
核心洞察
Gallant (搜索) announced a landmark partnership with MWI Animal Health (搜索) to create the first-ever ultra-low temperature cold chain for veterinary medicine, supporting the anticipated first FDA-approved off-the-shelf stem cell therapy for pets.
The collaboration will enable delivery of sonruvetcel (搜索), a potential first-in-class uterine-derived mesenchymal stromal cell (搜索) therapy for cats with refractory feline chronic gingivostomatitis (搜索), requiring storage at -80°C.
Survey data shows 95% of veterinary professionals believe stem cell therapy will become standard treatment within the next decade, with 93% more likely to offer regenerative therapies if they were off-the-shelf and delivered through simple IV protocols.
Gallant (搜索), an animal health biotechnology company, has announced a landmark fulfillment agreement with MWI Animal Health (搜索) (MWI), part of global healthcare company Cencora, to create the first-ever ultra-low temperature cold chain for veterinary medicine. The partnership comes as Gallant advances toward delivering what could be the first FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM).
Pioneering Stem Cell Therapy for Feline Disease
The first expected product from Gallant (搜索)'s pipeline is sonruvetcel (搜索) injectable suspension, a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell (搜索) (MSC) therapy for cats with refractory feline chronic gingivostomatitis (搜索) (rFCGS). The partnership with MWI will enable reliable delivery of veterinary stem cell therapies requiring storage at -80°C, addressing a critical infrastructure gap in veterinary medicine.
"Breakthrough science only matters if we can safely and reliably put it into the hands of veterinary professionals," said Dr. Linda Black, DVM, Ph.D., CEO of Gallant (搜索). "With MWI, we are pairing regenerative medicine innovation with world class supply chain management. This partnership helps ensure that, once approved, veterinarians can conveniently access an FDA-regulated, off-the-shelf stem cell therapy with confidence in its quality and integrity."
Addressing Distribution Challenges
The ultra-low temperature requirements for stem cell therapies have historically presented significant logistical challenges for veterinary practices. Julia Loew, CCO at MWI Animal Health (搜索), emphasized the importance of precision handling: "This partnership demonstrates how distribution innovation can unlock clinical innovation. Stem cell therapies require precision handling. By investing in ultra-low temperature logistics tailored to veterinary practice, we are ensuring that this category of innovation can be delivered to clinics in the exact state intended, ready for safe and effective use."
Under the agreement, MWI will develop and deploy a scalable, ultra-low temperature fulfillment model supporting nationwide availability through overnight shipping from MWI's Edwardsville, Kansas, distribution center. The system will ensure access for clinics across the continental United States and in noncontiguous U.S. markets, including Alaska, Hawaii, and Puerto Rico.
Strong Veterinary Professional Interest
Recent survey data conducted by Gallant (搜索) in collaboration with the American Animal Hospital Association (搜索) (AAHA) reveals significant interest in stem cell therapies among veterinary professionals. The survey found that nearly 95% of veterinary professionals believe stem cell therapy will become a standard treatment option within the next decade. Additionally, 79% say they are likely to use or recommend stem cell therapy in the future, and 93% report they would be more likely to offer regenerative therapies in-house if they were off-the-shelf and delivered through a simple IV protocol.
Broader Pipeline Implications
The companies expect the partnership to serve as a model by establishing infrastructure that can support Gallant (搜索)'s broader pipeline of disease-modifying therapies targeting inflammatory and degenerative conditions in companion animals. This foundational work positions both companies to expand access to regenerative medicine treatments as additional therapies advance through development.
The Gallant (搜索)-MWI partnership directly addresses veterinary professionals' expectations and practice needs by pairing an anticipated FDA-regulated, donor-derived stem cell therapy with a clinic-friendly fulfillment model, potentially transforming how regenerative medicine is delivered in veterinary care.